NCT00267085 - Synthetic Vaccine in Patients With Chronic Myeloid Leukemia and Minimal Residual Disease | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

December 31, 2005

Primary Completion Date

July 31, 2008

Study Completion Date

July 31, 2008

Conditions

Chronic Myeloid LeukemiaMinimal Residual Disease

Interventions

BIOLOGICAL

Synthetic Tumor-Specific Breakpoint Peptide Vaccine

CML vaccine, Imatinib mesylate, subcutaneously every 2 weeks x 4 weeks, then every three weeks x 1 week, then monthly for 10 months

Trial Locations (1)

UT MD Anderson Cancer Center, Houston